EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening

Harry Hill, Cristina Roadevin, Stephen Duffy, Olena Mandrik, Adam Brentnall

JAMA Network Open · 05.09.2024 · 7 (9) · e2431715

DOI: 10.1001/jamanetworkopen.2024.31715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.09.2024. Verfasst von Harry Hill und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Cost-Benefit Analysis, Early Detection of Cancer, Artificial Intelligence. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Previous research has shown good discrimination of short-term risk using an artificial intelligence (AI) risk prediction model (Mirai). However, no studies have been undertaken to evaluate whether this might translate into economic gains.

Objective

To assess the cost-effectiveness of incorporating risk-stratified screening using a breast cancer AI model into the United Kingdom (UK) National Breast Cancer Screening Program. Design, Setting, and Participants This study, conducted from January 1, 2023, to January 31, 2024, involved the development of a decision analytical model to estimate health-related quality of life, cancer survival rates, and costs over the lifetime of the female population eligible for screening. The analysis took a UK payer perspective, and the simulated cohort consisted of women aged 50 to 70 years at screening. Exposures Mammography screening at 1 to 6 yearly screening intervals based on breast cancer risk and standard care (screening every 3 years). Main Outcomes and Measures Incremental net monetary benefit based on quality-adjusted life-years (QALYs) and National Health Service (NHS) costs (given in pounds sterling; to convert to US dollars, multiply by 1.28).

Results

Artificial intelligence–based risk-stratified programs were estimated to be cost-saving and increase QALYs compared with the current screening program. A screening schedule of every 6 years for lowest-risk individuals, biannually and triennially for those below and above average risk, respectively, and annually for those at highest risk was estimated to give yearly net monetary benefits within the NHS of approximately £60.4 (US $77.3) million and £85.3 (US $109.2) million, with QALY values set at £20 000 (US $25 600) and £30 000 (US $38 400), respectively. Even in scenarios where decision-makers hesitate to allocate additional NHS resources toward screening, implementing the proposed strategies at a QALY value of £1 (US $1.28) was estimated to generate a yearly monetary benefit of approximately £10.6 (US $13.6) million. Conclusions and Relevance In this decision analytical model study of integrating risk-stratified screening with a breast cancer AI model into the UK National Breast Cancer Screening Program, risk-stratified screening was likely to be cost-effective, yielding added health benefits at reduced costs. These results are particularly relevant for health care settings where resources are under pressure. New studies to prospectively evaluate AI-guided screening appear warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCost-Benefit AnalysisEarly Detection of CancerArtificial IntelligenceHumansFemaleMiddle AgedUnited KingdomAgedMammographyQuality-Adjusted Life YearsRisk AssessmentMass Screening

Autor:innen und Institutionen

  • School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
  • Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, United Kingdom.
  • Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.

Zitieren

APA

Hill, H., Roadevin, C., Duffy, S., Mandrik, O., & Brentnall, A. (2024). Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening. JAMA Network Open, 7(9), e2431715. https://doi.org/10.1001/jamanetworkopen.2024.31715

Vancouver

Hill H, Roadevin C, Duffy S, Mandrik O, Brentnall A. Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening. JAMA Network Open. 2024;7(9):e2431715. doi:10.1001/jamanetworkopen.2024.31715

BibTeX
@article{Hill2024,
  author = {Hill, Harry and Roadevin, Cristina and Duffy, Stephen and Mandrik, Olena and Brentnall, Adam},
  title = {Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {9},
  pages = {e2431715},
  doi = {10.1001/jamanetworkopen.2024.31715}
}
Kostenlos starten →